Protocol Ledger

NCT03827655 · Phase II · COMPLETED

A Study of TAK-954 to Treat Gastrointestinal Dysfunction in Adults After Surgery

Interventional Phase II clinical trial protocol NCT03827655 sponsored by Takeda in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-03-07 Enrollment: 209 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03827655
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)209 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03827655
Protocol FieldVerified Registry Value
NCT IdentifierNCT03827655
Consolidated Lead SponsorTakeda
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment209 participants (ACTUAL)
Registered Start Date2019-03-07
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Takeda across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI